Institute For Gene And Cell Therapies
| Fiscal year | Revenue | Expenses | Net | Reserve mo. | Staff % |
|---|---|---|---|---|---|
| 2019 | 510,000 | 138,823 | 371,177 | 32.1 | 0% |
| 2020 | 550,000 | 871,510 | −321,510 | 0.7 | 0% |
| 2021 | 1,200,000 | 1,118,949 | 81,051 | 1.4 | 0% |
| 2022 | 1,325,000 | 1,103,289 | 221,711 | 3.8 | 0% |
| 2023 | 1,400,439 | 1,158,630 | 241,809 | 6.2 | 0% |
In its most recent public year (2023), this organization brought in $241,809 more than it spent. Its reserves stood at about 6.2 months of spending, down from 32.1 in 2019. Staff pay was 0% of spending.
Reserve months = net assets ÷ average monthly spending; net assets count everything the organization owns beyond its debts — buildings and donor-restricted funds included, not just cash. Staff pay = salaries, wages, and officer compensation; it excludes benefits and payroll taxes. The IRS releases this data years after the fact — this organization's newest public year is 2023. Years refer to the calendar year in which the organization's fiscal year ended. Short-form filers do not publicly report donor-restricted balances or staffing costs. Source filings
Institute For Gene And Cell Therapies's IRS filings as a feed — one entry per filing year, through 2023. Add the address to any feed reader; in Slack, send /feed subscribe with it (pasting the link alone won't subscribe). How this feed works